Search

Displaying results 2051 - 2060 of 10000 in total
  1. Drug

    Danicopan

    go.drugbank.com/drugs/DB15401
    ApprovedInvestigational

    [A263501] Standard therapy for PNH involves the use of complement C5 inhibitors (e.g. … [A263501,L50411] Danicopan is a small molecule complement factor D inhibitor that selectively blocks the alternative pathway, thereby working to address extravascular hemolysis when used in conjunction

    Categories: Complement Factor D InhibitorSynonyms: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide, (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamide
  2. Drug

    Spesolimab

    go.drugbank.com/drugs/DB15626
    ApprovedInvestigational

    in December 2022 for the treatment of flares in adult patients with generalized pustular psoriasis. … The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares.

  3. Drug

    Melphalan

    go.drugbank.com/drugs/DB01042
    ApprovedInvestigational

    [L40928] It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. … Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent.

    Synonyms: 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine, p-Di-(2-chloroethyl)amino-L-phenylalanine
  4. Drug

    Vinblastine

    go.drugbank.com/drugs/DB00570
    ApprovedInvestigational

    Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

  5. Drug

    Acetarsol

    go.drugbank.com/drugs/DB13268
    ApprovedWithdrawn

    [L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964. … Acetarsol, with the molecular formula N-acetyl-4-hydroxy-m-arsanilic acid, is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties.

  6. Drug

    Oxcarbazepine

    go.drugbank.com/drugs/DB00776
    ApprovedInvestigational

    [L8627,L8630,L8633] It is a structural derivative of [carbamazepine][A186101] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood … Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.

    Categories: Metabolic Side Effects of Drugs and Substances
  7. Drug

    Relebactam

    go.drugbank.com/drugs/DB12377
    ApprovedInvestigational

    [label] It is considered to be a last-line treatment option and gained FDA approval as part of the combination product RecarbrioⓇ in July 2019.[L7568] … infections in adults.

  8. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  9. Drug

    Sumanirole

    go.drugbank.com/drugs/DB06477
    Investigational

  10. Drug

    Rosin

    go.drugbank.com/drugs/DB11165
    Approved

    Rosin has shown to mediate antibacterial actions on Gram-positive bacterial species [A27267]. … Rosin is a solid form of resin obtained from pines and other plants, mostly conifers. It is prepared from heating fresh liquid resin to vaporize the volatile liquid terpene components.

    Categories: Compounds used in a research, industrial, or household setting